Literature DB >> 12590165

Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology.

Milos D Ikonomovic1, Elliott J Mufson, Joanne Wuu, Elizabeth J Cochran, David A Bennett, Steven T DeKosky.   

Abstract

Several recent studies indicate that activity of cholinergic enzymes in the cortex of people with mild cognitive impairment (MCI) and early Alzheimer's disease (AD) are preserved. We correlated levels of hippocampal choline acetyltransferase (ChAT) activity with the extent of AD lesions in subjects from the Religious Order Study, including cases with no cognitive impairment (NCI), MCI, and with mild to moderate AD. Hippocampal ChAT activity levels were also determined in a group of end-stage AD patients who were enrolled in the University of Pittsburgh Alzheimer's Disease Research Center. MCI subjects were characterized with increased hippocampal ChAT activity. This elevation was no longer present in mild AD cases, which were not different from NCI subjects. Severe AD cases showed markedly depleted hippocampal ChAT levels. In NCI, MCI, and mild-moderate AD, there was a positive correlation between hippocampal ChAT activity levels and progression of neuritic plaque pathology in entorhinal cortex and hippocampus. A significant elevation of hippocampal ChAT in the MCI group was found selectively in the limbic (i.e., entorhinal-hippocampal, III/IV) Braak stages. We hypothesize that cholinergic changes in the hippocampus of MCI subjects reflect a compensatory response to the progressive denervation of the hippocampus by lost entorhinal cortex input. Moreover, the present findings suggest that the short-term memory loss observed in MCI is not caused by cholinergic deficits; it more likely relates to disrupted entorhinal-hippocampal connectivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590165     DOI: 10.3233/jad-2003-5106

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  43 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

Review 2.  Utility of nutraceutical products marketed for cognitive and memory enhancement.

Authors:  Graham J McDougall; Vonnette Austin-Wells; Teena Zimmerman
Journal:  J Holist Nurs       Date:  2005-12

3.  Familial risk for Alzheimer's disease alters fMRI activation patterns.

Authors:  Susan Spear Bassett; David M Yousem; Catherine Cristinzio; Ivana Kusevic; Michael A Yassa; Brian S Caffo; Scott L Zeger
Journal:  Brain       Date:  2006-05       Impact factor: 13.501

4.  Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2014-04-15       Impact factor: 3.215

5.  Anticholinergic Drug Use and Risk to Cognitive Performance in Older Adults with Questionable Cognitive Impairment: A Cross-Sectional Analysis.

Authors:  Sunil Swami; Ronald A Cohen; John A Kairalla; Todd M Manini
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

Review 6.  Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  J Neural Transm (Vienna)       Date:  2015-05-06       Impact factor: 3.575

Review 7.  Hippocampal plasticity during the progression of Alzheimer's disease.

Authors:  E J Mufson; L Mahady; D Waters; S E Counts; S E Perez; S T DeKosky; S D Ginsberg; M D Ikonomovic; S W Scheff; L I Binder
Journal:  Neuroscience       Date:  2015-03-12       Impact factor: 3.590

8.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

9.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

10.  Cerebrovascular smooth muscle actin is increased in nondemented subjects with frequent senile plaques at autopsy: implications for the pathogenesis of Alzheimer disease.

Authors:  Christine M Hulette; John F Ervin; Yvette Edmonds; Samantha Antoine; Nicolas Stewart; Mari H Szymanski; Kathleen M Hayden; Carl F Pieper; James R Burke; Kathleen A Welsh-Bohmer
Journal:  J Neuropathol Exp Neurol       Date:  2009-04       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.